🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Kerendia 10 mg film coated tablets, Kerendia 20 mg film-coated tablets, Finerenone/Kerendia 10mg and 20mg Placebo equal to test product except active substance, Empagliflozin/Jardiance 10mg Placebo equal to test product except active substance, Jardiance 10 mg film-coated tablets

    Bayer AG

    Chronic kidney disease in type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  2. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  3. L-Histidine, L-Histidine monohydrochloride monohydrate, Mannitol, Sucrose, Disodium EDTA dihydrate, Polysorbate 80, Water for injection

    Tour Hekla

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  4. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  6. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  7. LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN

    Novartis Pharmaceuticals

    Heart Failure

    phase 2 small molecule active

    1 trial

  8. LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial

  9. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  10. Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer

    Bayer AG

    Solid tumors harboring NTRK fusion

    phase 2 small molecule active

    1 trial

  11. Lemborexant

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interaction

    phase 2 small molecule completed

    1 trial

  12. Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, IMBRUVICA 140 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 15 mg hard capsules, JNJ-54179060, Lenalidomide Accord 2.5 mg hard capsules, Ruxi

    Janssen-Cilag International N.V.

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  13. Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    phase 2 small molecule active

    1 trial

  14. Lifitegrast

    Takeda

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  15. Light-activated AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  16. Lintuzumab-Ac225

    Actinium Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 mab active

    2 trials

  17. Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone 4 mg tablets, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. Linvoseltamab, Linvoseltamab, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Diphenhydramine Hydrochloride 25 mg Tablets, Paracetamol 500mg Tablets, REGN88, Dexamethasone 2mg Tablets

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  19. Liposuction

    The First People's Hospital of Lianyungang

    Anterior Cruciate Ligament Partial Rupture

    phase 2 other active

    1 trial

  20. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  21. Lonsurf 15 mg/6.14 mg film-coated tablets, IRINOTECAN, Bemarituzumab, PACLITAXEL, RAMUCIRUMAB

    The George Institute

    FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

    phase 2 small molecule active

    1 trial

  22. Lorundrostat

    Mineralys Therapeutics

    Obstructive Sleep Apnea

    phase 2 small molecule completed

    1 trial

  23. Losmapimod

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  24. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources